Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis
Abstract Background Capacity to work is impacted by psoriatic arthritis (PsA). Our objective was to describe the course of work productivity and leisure activity in patients with PsA treated with biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs). Methods A syste...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-024-03282-0 |
| _version_ | 1797273649228546048 |
|---|---|
| author | Laure Gossec Brittany Humphries Megan Rutherford Vanessa Taieb Damon Willems William Tillett |
| author_facet | Laure Gossec Brittany Humphries Megan Rutherford Vanessa Taieb Damon Willems William Tillett |
| author_sort | Laure Gossec |
| collection | DOAJ |
| description | Abstract Background Capacity to work is impacted by psoriatic arthritis (PsA). Our objective was to describe the course of work productivity and leisure activity in patients with PsA treated with biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs). Methods A systematic literature review identified all trials and observational studies published January 1, 2010–October 22, 2021, reporting work productivity using the Work Productivity and Activity Impairment Questionnaire (WPAI) in patients with PsA treated with b/tsDMARDs. Outcomes for WPAI domains (absenteeism, presenteeism, total work productivity, and activity impairment) were collected at baseline and time point closest to 24 weeks of treatment. A random effects meta-analysis of single means was conducted to calculate an overall absolute mean change from baseline for each WPAI domain. Results Twelve studies (ten randomized controlled and two observational) assessing patients treated with adalimumab, bimekizumab, guselkumab, ixekizumab, risankizumab, secukinumab, or upadacitinib were analysed. Among 3741 employed patients, overall mean baseline scores were 11.4%, 38.7%, 42.7%, and 48.9% for absenteeism, presenteeism, total work productivity impairment, and activity impairment, respectively. Estimated absolute mean improvements (95% confidence interval) to week 24 were 2.4 percentage points (%p) (0.6, 4.1), 17.8%p (16.2,19.3), 17.6%p (15.9,19.4), and 19.3%p (17.6, 21.0) respectively, leading to a mean relative improvement of 41% for total work productivity. The change in work outcomes in the b/tsDMARDs appeared similar. Conclusions This systematic literature review and meta-analysis confirmed that patients with active PsA have a substantially reduced capacity to work and participate in leisure activities. Substantial improvements across various WPAI domains were noted after 24 weeks of b/tsDMARD treatment, especially in presenteeism, total work productivity, and activity impairment. These findings may be useful for reimbursement purposes and in the context of shared decision-making. Key summary points This systematic literature review (SLR) of randomized clinical trials and observational studies of biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs b/tsDMARDs in patients with PsA found that at treatment introduction, patients presented with a 42.7% mean productivity loss per week as assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire. Through a meta-analysis comparing before/after values without adjustment for placebo response, we found that after 24 weeks of treatment with b/tsDMARDs, there was a mean absolute improvement of 17.6 percentage points and a mean relative improvement of 41% in total work productivity, with similar magnitudes of improvement in time spent at work and regular activities outside of work. These results provide clinical-, regulatory- and reimbursement decision-makers with data on the potential societal and socio-economic benefits of b/tsDMARDs in PsA. |
| first_indexed | 2024-03-07T14:47:25Z |
| format | Article |
| id | doaj.art-28a4eabc81ff4c4f8c7874349bf07c2b |
| institution | Directory Open Access Journal |
| issn | 1478-6362 |
| language | English |
| last_indexed | 2024-03-07T14:47:25Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj.art-28a4eabc81ff4c4f8c7874349bf07c2b2024-03-05T19:51:49ZengBMCArthritis Research & Therapy1478-63622024-02-0126111510.1186/s13075-024-03282-0Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysisLaure Gossec0Brittany Humphries1Megan Rutherford2Vanessa Taieb3Damon Willems4William Tillett5Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé PubliqueDepartment of Health Research Methods, Evidence and Impact, McMaster UniversityCytel IncUCB PharmaUCB PharmaDepartment of Life Sciences, Royal National Hospital for Rheumatic Diseases, Centre for Therapeutic Innovation University of BathAbstract Background Capacity to work is impacted by psoriatic arthritis (PsA). Our objective was to describe the course of work productivity and leisure activity in patients with PsA treated with biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs). Methods A systematic literature review identified all trials and observational studies published January 1, 2010–October 22, 2021, reporting work productivity using the Work Productivity and Activity Impairment Questionnaire (WPAI) in patients with PsA treated with b/tsDMARDs. Outcomes for WPAI domains (absenteeism, presenteeism, total work productivity, and activity impairment) were collected at baseline and time point closest to 24 weeks of treatment. A random effects meta-analysis of single means was conducted to calculate an overall absolute mean change from baseline for each WPAI domain. Results Twelve studies (ten randomized controlled and two observational) assessing patients treated with adalimumab, bimekizumab, guselkumab, ixekizumab, risankizumab, secukinumab, or upadacitinib were analysed. Among 3741 employed patients, overall mean baseline scores were 11.4%, 38.7%, 42.7%, and 48.9% for absenteeism, presenteeism, total work productivity impairment, and activity impairment, respectively. Estimated absolute mean improvements (95% confidence interval) to week 24 were 2.4 percentage points (%p) (0.6, 4.1), 17.8%p (16.2,19.3), 17.6%p (15.9,19.4), and 19.3%p (17.6, 21.0) respectively, leading to a mean relative improvement of 41% for total work productivity. The change in work outcomes in the b/tsDMARDs appeared similar. Conclusions This systematic literature review and meta-analysis confirmed that patients with active PsA have a substantially reduced capacity to work and participate in leisure activities. Substantial improvements across various WPAI domains were noted after 24 weeks of b/tsDMARD treatment, especially in presenteeism, total work productivity, and activity impairment. These findings may be useful for reimbursement purposes and in the context of shared decision-making. Key summary points This systematic literature review (SLR) of randomized clinical trials and observational studies of biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs b/tsDMARDs in patients with PsA found that at treatment introduction, patients presented with a 42.7% mean productivity loss per week as assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire. Through a meta-analysis comparing before/after values without adjustment for placebo response, we found that after 24 weeks of treatment with b/tsDMARDs, there was a mean absolute improvement of 17.6 percentage points and a mean relative improvement of 41% in total work productivity, with similar magnitudes of improvement in time spent at work and regular activities outside of work. These results provide clinical-, regulatory- and reimbursement decision-makers with data on the potential societal and socio-economic benefits of b/tsDMARDs in PsA.https://doi.org/10.1186/s13075-024-03282-0Psoriatic arthritisWork productivityWPAIProductivity cost |
| spellingShingle | Laure Gossec Brittany Humphries Megan Rutherford Vanessa Taieb Damon Willems William Tillett Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis Arthritis Research & Therapy Psoriatic arthritis Work productivity WPAI Productivity cost |
| title | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis |
| title_full | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis |
| title_fullStr | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis |
| title_full_unstemmed | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis |
| title_short | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis |
| title_sort | improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs a systematic literature review and meta analysis |
| topic | Psoriatic arthritis Work productivity WPAI Productivity cost |
| url | https://doi.org/10.1186/s13075-024-03282-0 |
| work_keys_str_mv | AT lauregossec improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis AT brittanyhumphries improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis AT meganrutherford improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis AT vanessataieb improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis AT damonwillems improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis AT williamtillett improvementinworkproductivityamongpsoriaticarthritispatientstreatedwithbiologicortargetedsyntheticdrugsasystematicliteraturereviewandmetaanalysis |